{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:57:02Z","timestamp":1760122622101,"version":"3.33.0"},"reference-count":0,"publisher":"Canadian Society of Healthcare-Systems Pharmacy","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJHP"],"abstract":"<jats:p>&lt;p&gt;&lt;strong&gt;ABSTRACT&lt;\/strong&gt;&lt;\/p&gt;&lt;p&gt;&lt;strong&gt;Background:&lt;\/strong&gt; Current guidelines recommend triple antithrombotic therapy (TAT), defined as acetylsalicylic acid (ASA), clopidogrel, and warfarin, for patients with nonvalvular atrial fibrillation who have undergone percutaneous coronary intervention with stent implantation. The choice of anticoagulant\/antiplatelet therapy in this population is ambiguous and complex, and prescribing patterns are not well documented.&lt;\/p&gt;&lt;p&gt;&lt;strong&gt;Objective:&lt;\/strong&gt; To characterize local prescribing patterns for anticoagulant\/antiplatelet therapy after percutaneous coronary intervention in patients with nonvalvular atrial fibrillation.&lt;\/p&gt;&lt;p&gt;&lt;strong&gt;Methods:&lt;\/strong&gt; A chart review was conducted at a single quaternary cardiology centre. Patients with nonvalvular atrial fibrillation were identified via medical records, and those who underwent percutaneous coronary intervention were identified using a local clinical patient registry. Adult inpatients with nonvalvular atrial fibrillation and a CHADS2 score (based on congestive heart failure, hypertension, age \u2265 75 years, diabetes mellitus, prior stroke) of 1 or higher who underwent percutaneous coronary intervention from 2011 to 2013 were included. Patients undergoing cardiovascular surgery or transcatheter aortic valve replacement, those with mechanical devices requiring anticoagulation, and those with an allergy to any component of TAT were excluded.&lt;\/p&gt;&lt;p&gt;&lt;strong&gt;Results:&lt;\/strong&gt; Seventy patients were included. The median age was 75 years, and 52 (74%) were men. At discharge, 30 (43%) were receiving TAT and 27 (39%) were receiving dual antiplatelet therapy (clopidogrel and ASA). No patients received the combination of warfarin and clopidogrel. Among those who received TAT, 90% (19 of 21) who received a bare metal stent had a recommended duration of 1 month, and 75% (6 of 8) who received a drug-eluting stent had a recommended duration of 1 year. Direct-acting oral anticoagulants with 2 antiplatelet drugs were prescribed for 9% (6 of 70) of the patients, and 10% (7 of 70) received ticagrelor and ASA with or without warfarin. Overall, the combination of ASA, oral anticoagulant, and P2Y12 inhibitor was used for 54% (38\/70) of the patients.&lt;\/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions:&lt;\/strong&gt; Fewer than half of the patients in this study received TAT, and almost 20% received no\u2013evidence-based therapy with a direct-acting oral anticoagulant or ticagrelor, alone or in combination. Despite current guideline recommendations, the rate of TAT utilization was lower than rates reported in the literature.&lt;\/p&gt;&lt;p&gt;&lt;strong&gt;R\u00c9SUM\u00c9&lt;\/strong&gt;&lt;\/p&gt;&lt;p&gt;&lt;strong&gt;Contexte :&lt;\/strong&gt; Les lignes directrices actuelles recommandent une trith\u00e9rapie antithrombotique, compos\u00e9e d\u2019acide ac\u00e9tylsalicylique (AAS), de clopidogrel et de warfarine, pour les patients atteints de fibrillation auriculaire non valvulaire qui ont subi l\u2019implantation d\u2019une endoproth\u00e8se par intervention coronarienne percutan\u00e9e. Le choix de traitement par anticoagulant ou antiplaquettaire pour cette population est ambigu et complexe. De plus, les habitudes de prescription ne sont pas bien document\u00e9es.&lt;\/p&gt;&lt;p&gt;&lt;strong&gt;Objectif :&lt;\/strong&gt; Offrir un portrait des habitudes locales de prescription de traitements par anticoagulant ou antiplaquettaire suite \u00e0 une intervention coronarienne percutan\u00e9e chez les patients atteints de fibrillation auriculaire non valvulaire.&lt;\/p&gt;&lt;p&gt;&lt;strong&gt;M\u00e9thodes :&lt;\/strong&gt; Une analyse des dossiers m\u00e9dicaux a \u00e9t\u00e9 men\u00e9e dans un seul centre quaternaire de cardiologie. Les patients atteints de fibrillation auriculaire non valvulaire ont \u00e9t\u00e9 identifi\u00e9s \u00e0 l\u2019aide de leurs dossiers m\u00e9dicaux. Ceux qui avaient subi une intervention coronarienne percutan\u00e9e ont \u00e9t\u00e9 trouv\u00e9s en consultant un registre local de patients. Les patients adultes hospitalis\u00e9s qui souffraient d\u2019une fibrillation auriculaire non valvulaire, qui pr\u00e9sentaient un score CHADS2 de 1 ou plus (calcul\u00e9 en fonction de la pr\u00e9sence d\u2019insuffisance cardiaque congestive, d\u2019hypertension, d\u2019\u00e2ge \u00e9gal ou sup\u00e9rieur \u00e0 75 ans, de diab\u00e8te et d\u2019accident vasculaire c\u00e9r\u00e9bral ant\u00e9rieur) et qui avaient subi une intervention coronarienne percutan\u00e9e entre 2011 et 2013 ont \u00e9t\u00e9 admis. Les patients qui avaient subi une chirurgie cardiovasculaire ou un remplacement valvulaire aortique par cath\u00e9ter, ceux dot\u00e9s de proth\u00e8ses m\u00e9caniques n\u00e9cessitant une anticoaguloth\u00e9rapie et ceux allergiques \u00e0 un ou plusieurs \u00e9l\u00e9ments de la trith\u00e9rapie antithrombotique ont \u00e9t\u00e9 exclus.&lt;\/p&gt;&lt;p&gt;&lt;strong&gt;R\u00e9sultats :&lt;\/strong&gt; L\u2019\u00e2ge m\u00e9dian des 70 patients admis \u00e9tait de 75 ans et 52 d\u2019entre eux \u00e9taient des hommes. Au moment du cong\u00e9, 30 (43 %) recevaient une trith\u00e9rapie antithrombotique et 27 (39 %) recevaient une bith\u00e9rapie antiplaquettaire (AAS et clopidogrel). Aucun patient n\u2019a re\u00e7u une association de warfarine et de clopidogrel. Parmi ceux qui ont re\u00e7u une trith\u00e9rapie antithrombotique, la dur\u00e9e recommand\u00e9e du traitement \u00e9tait d\u2019un mois pour 90 % (19 sur 21) de ceux qui ont re\u00e7u une endoproth\u00e8se m\u00e9tallique nue et d\u2019un an pour 75 % (6 sur 8) de ceux qui ont re\u00e7u une endoproth\u00e8se \u00e0 \u00e9lution de m\u00e9dicaments. On a prescrit pour 9 % (6 sur 70) des patients un anticoagulant oral direct accompagn\u00e9 de deux antiplaquettaires. De plus, 10 % (7 sur 70) des patients ont re\u00e7u du ticagrelor et de l\u2019AAS avec ou sans warfarine. Dans l\u2019ensemble, la combinaison d\u2019AAS, d\u2019un anticoagulant oral et d\u2019un inhibiteur du P2Y12 a \u00e9t\u00e9 employ\u00e9e chez 54 % (38 sur 70) des patients.&lt;\/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions :&lt;\/strong&gt; Moins de la moiti\u00e9 des patients de la pr\u00e9sente \u00e9tude ont re\u00e7u une trith\u00e9rapie antithrombotique et pr\u00e8s de 20 % ont re\u00e7u un traitement non fond\u00e9 sur des donn\u00e9es probantes compos\u00e9 d\u2019un anticoagulant oral direct ou de ticagrelor, employ\u00e9s seuls ou en association. Malgr\u00e9 les recommandations des lignes directrices actuelles, le taux de recours \u00e0 la trith\u00e9rapie antithrombotique \u00e9tait plus faible que les pourcentages pr\u00e9sent\u00e9s dans la litt\u00e9rature.&lt;\/p&gt;<\/jats:p>","DOI":"10.4212\/cjhp.v69i4.1574","type":"journal-article","created":{"date-parts":[[2016,8,31]],"date-time":"2016-08-31T13:10:21Z","timestamp":1472649021000},"source":"Crossref","is-referenced-by-count":3,"title":["Anticoagulant and Antiplatelet Prescribing Patterns for Patients with Atrial Fibrillation after Percutaneous Coronary Intervention"],"prefix":"10.4212","volume":"69","author":[{"given":"Erin A","family":"Woods","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret L","family":"Ackman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle M","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheri L","family":"Koshman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosaleen M","family":"Boswell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arden R","family":"Barry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2732","published-online":{"date-parts":[[2016,8,31]]},"container-title":["The Canadian Journal of Hospital Pharmacy"],"original-title":[],"link":[{"URL":"http:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/viewFile\/1574\/2381","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/viewFile\/1574\/2397","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/viewFile\/1574\/2381","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/viewFile\/1574\/2397","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,8,31]],"date-time":"2016-08-31T13:10:23Z","timestamp":1472649023000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/view\/1574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,31]]},"references-count":0,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,8,31]]}},"URL":"https:\/\/doi.org\/10.4212\/cjhp.v69i4.1574","relation":{},"ISSN":["1920-2903","0008-4123"],"issn-type":[{"type":"electronic","value":"1920-2903"},{"type":"print","value":"0008-4123"}],"subject":[],"published":{"date-parts":[[2016,8,31]]}}}